1. Favorable histology, MYCN-amplified 4S neonatal neuroblastoma.
- Author
-
Chan EL, Harris RE, Emery KH, Gelfand MJ, Collins MH, and Gruppo RA
- Subjects
- Adrenal Gland Neoplasms congenital, Adrenal Gland Neoplasms drug therapy, Adrenal Gland Neoplasms metabolism, Adrenal Gland Neoplasms pathology, Adrenal Gland Neoplasms surgery, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor blood, Biomarkers, Tumor urine, Carboplatin administration & dosage, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Etoposide administration & dosage, Female, Gene Amplification, Hepatomegaly etiology, Humans, Infant, Newborn, Isotretinoin administration & dosage, Liver Neoplasms blood, Liver Neoplasms congenital, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Lymphatic Metastasis, Magnetic Resonance Imaging, Neuroblastoma congenital, Neuroblastoma drug therapy, Neuroblastoma metabolism, Neuroblastoma pathology, Neuroblastoma secondary, Neuroblastoma surgery, Prognosis, Remission Induction, Risk Factors, Adrenal Gland Neoplasms genetics, Genes, Neoplasm, Genes, myc, Neuroblastoma genetics
- Abstract
We report a neonate with 4S neuroblastoma and MYCN amplification, but favorable Shimada histology, successfully treated with chemotherapy and 13-cis-retinoic acid without stem cell transplantation. MYCN amplification in neuroblastoma is usually associated with unfavorable Shimada histology; the presence of these features in infants with 4S disease confers a poor prognosis. A small number of infants with 4S neuroblastoma and MYCN amplification have favorable Shimada histology. In this subgroup of infants, histopathology may be equally important in predicting outcome.
- Published
- 2007
- Full Text
- View/download PDF